Robinhood shares gain on Q2 beat, as user and crypto growth accelerate
On Wednesday, Jefferies initiated coverage on Krystal Biotech shares (NASDAQ:KRYS), assigning a Buy rating and setting a price target of $245.00. Currently trading at $175.22, the stock has garnered strong analyst support with a consensus recommendation of 1.4 (Strong Buy). Krystal Biotech, a commercial-stage biotechnology company valued at $5.05 billion, is recognized for its focus on local gene delivery. Its lead drug, Vyjuvek (COL7A1), is distinguished as the first and only approved treatment for Dystrophic Epidermolysis Bullosa (DEB) and has demonstrated solid performance two years post-launch. According to InvestingPro, the company maintains impressive gross profit margins of 93.09%.
The Jefferies analyst anticipates that Vyjuvek will continue to see steady growth and is poised to achieve blockbuster status within a few years. This optimism appears well-founded, as the company has demonstrated remarkable revenue growth of 473% in the last twelve months. This growth is expected to be supported by deeper market penetration, both globally and in the ocular segment. The company’s expansion strategy is underpinned by a robust pipeline of development programs in Cystic Fibrosis (CF), Alpha-1 Antitrypsin Deficiency (AATD), oncology, and dermatology. These programs leverage Krystal Biotech’s proprietary, in-house gene delivery technology, which the analyst believes could drive additional upside for the company.
Krystal Biotech’s proprietary technology platform has been instrumental in developing its gene therapy products. With a focus on rare diseases, the company has positioned itself as a leader in gene delivery to the skin and other tissues. The analyst’s positive outlook reflects confidence in the company’s ability to capitalize on its technological advancements and to address unmet medical needs in various therapeutic areas.
The Jefferies analyst’s remarks underscore the potential for Krystal Biotech’s lead drug and its pipeline to contribute significantly to the company’s growth trajectory. "We see steady growth to achieve blockbuster status in few years, deepening penetration by accessing global and ocular markets," the analyst stated, highlighting the company’s strategic approach to expanding its reach.
Krystal Biotech’s ongoing development programs are expected to further enhance its portfolio and market presence. The company’s commitment to innovation in gene therapy positions it favorably for future growth, as it continues to explore opportunities in CF, AATD, oncology, and dermatology based on its gene delivery technology. InvestingPro analysis reveals an overall financial health score of "GREAT," with particularly strong metrics in growth and cash flow. Discover more insights about KRYS and access the comprehensive Pro Research Report, along with 11 additional ProTips, by subscribing to InvestingPro.
In other recent news, Krystal Biotech reported its 2024 financial results, showcasing an earnings per share (EPS) of $1.52 for the fourth quarter, which exceeded the expected $1.21. Despite a slight revenue miss with $91.1 million against a forecast of $91.63 million, the company’s overall performance remained strong, with total annual revenue from VYJUVEK reaching $290.5 million. H.C. Wainwright maintained its Buy rating and $221 price target on Krystal Biotech, highlighting the continued success and growth potential of VYJUVEK. The company is preparing for the European launch of VYJUVEK, targeting Germany for mid-2025 and France later in the year, following a favorable opinion from the European Medicines Agency. This expansion is significant given the large number of dystrophic epidermolysis bullosa (DEB) patients in these countries. Krystal Biotech also anticipates a decision from Japan’s Pharmaceuticals and Medical (TASE:BLWV) Devices Agency in the second half of 2025, further expanding its international market presence. Additionally, the company has secured over 510 reimbursement approvals in the U.S., demonstrating robust demand for VYJUVEK. These developments underscore Krystal Biotech’s strategic focus on global market expansion and sustained revenue growth.
This article was generated with the support of AI and reviewed by an editor. For more information see our T&C.